Published in J Allergy Clin Immunol on July 09, 2009
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol (2011) 1.30
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol (2014) 1.19
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol (2014) 1.14
Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn (2011) 1.06
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia (2015) 0.95
Current concepts on diagnosis and treatment of mastocytosis. Transl Med UniSa (2014) 0.91
Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol (2015) 0.90
Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology (2012) 0.89
Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporos Int (2013) 0.88
Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One (2013) 0.86
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol (2013) 0.86
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica (2011) 0.83
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int (2016) 0.83
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression. Leukemia (2015) 0.80
Targeted Treatment Options in Mastocytosis. Front Med (Lausanne) (2017) 0.76
3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages. Chem Biol Interact (2015) 0.76
Characterization of Mast Cell Activation Syndrome. Am J Med Sci (2016) 0.75
Indolent systemic mastocytosis without skin involvement vs. isolated bone marrow mastocytosis. Haematologica (2011) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74
Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood (2011) 2.14
Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol (2011) 1.78
Zinc-finger transcription factor Slug contributes to the function of the stem cell factor c-kit signaling pathway. Blood (2002) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. Blood (2008) 1.61
Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica (2010) 1.61
Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood (2006) 1.57
Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica (2005) 1.56
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53
Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J (2008) 1.52
Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol (2010) 1.46
Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS (2005) 1.44
Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood (2002) 1.44
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica (2009) 1.40
Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom (2010) 1.36
Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat Immunol (2009) 1.30
Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood (2004) 1.26
The nature of circulating CD27+CD43+ B cells. J Exp Med (2011) 1.22
Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol (2010) 1.22
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol (2009) 1.21
Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21
The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica (2006) 1.21
Conventional diagnostics in multiple myeloma. Eur J Cancer (2006) 1.20
Cancer development induced by graded expression of Snail in mice. Hum Mol Genet (2005) 1.18
Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A (2008) 1.16
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood (2013) 1.15
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood (2013) 1.14
Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol (2011) 1.14
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol (2009) 1.13
A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J (2012) 1.12
Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom (2010) 1.12
[Diagnosis and treatment of nocturnal paroxysmal hemoglobinuria]. Med Clin (Barc) (2010) 1.10
Flow cytometry criteria for systemic mastocytosis: bone marrow mast cell counts do not always count. Am J Clin Pathol (2013) 1.10
Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom (2007) 1.10
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica (2009) 1.08
Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol (2002) 1.07
Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol (2012) 1.07
Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res (2007) 1.06
Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood (2003) 1.06
TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder. Am J Pathol (2003) 1.05
A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clin Cancer Res (2009) 1.05
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol (2002) 1.05
Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood (2003) 1.04
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res (2004) 1.04
Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist (2007) 1.04
Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica (2004) 1.04
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica (2012) 1.04
Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom (2008) 1.03
Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol (2005) 1.03
Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol (2013) 1.01
Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol (2011) 1.01
Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom (2004) 1.01
Chronic alcohol consumption is associated with changes in the distribution, immunophenotype, and the inflammatory cytokine secretion profile of circulating dendritic cells. Alcohol Clin Exp Res (2007) 1.01
Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.01
Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol (2014) 1.00
Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol (2008) 1.00
Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol (2004) 1.00
Molecular characterization of a novel immune receptor restricted to the monocytic lineage. J Immunol (2004) 0.99
Multiparametric flow cytometry for identification and fluorescence activated cell sorting of five distinct B-cell subpopulations in normal tonsil tissue. Am J Clin Pathol (2011) 0.98
Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest (2008) 0.98
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom (2010) 0.98
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. Br J Haematol (2002) 0.97